Navigation Links
BIOARRAY Genetics Inc. Announces the Launch of a Novel Oncology Gene Panel
Date:4/6/2017

BIOARRAY Genetics Inc. (BIOARRAY), a clinical-stage molecular diagnostics company, announced the launch of a novel oncology gene panel, BA325, a research and development tool that accelerates drug discovery and development for cancer treatments by providing new information on cancer response to treatments. BA325 contains 32 genes that are currently drug treatment targets, and provides comprehensive information about oncology drug sensitivity and resistance.

BIOARRAY's BA325 RNA-biomarker panel was derived by querying normal organizational phenotypes. This phenotype-based approach identified genes important to epithelial cell organization in a physiologically relevant context. As a result the selected biomarkers have greater utility in testing tumor samples because 251 of the 325 genes identified are novel and not present in nine other commercially available oncology gene panels. While other oncology biomarker panels are proliferation centric, BIOARRAY's genes bring complementary information with diverse interconnected cell signaling pathways beyond proliferation.

"For more than a century pathologists have understood that there is a relationship between the microscopic structure of a tumor and clinical outcome. Even today, physicians use a tumor grading system based on the relative preservation of normal tissue and cell structures as a guide for treatment,” Edward C. Goodwin, CTO of BIOARRAY, said. “BA325 provides a rich source of gene expression patterns showing how tumors deviate from their normal state, and provides novel guidance for drug development and rationale for companion diagnostics for new therapies, including immuno-oncology drugs."

This week at the 2017 Annual Meeting of the American Association for Cancer Research in Washington, DC, BIOARRAY presented recent studies describing details of BA325's cell signaling pathways network coverage and technical validation of the assay.

"Aligning with the Cancer Moonshot program, we're offering evidence-based predictive diagnostics that will benefit cancer patients by providing actionable information about their treatment options. BA325 brings a new perspective to complement current available information on how drugs work or don't work,” Marcia Fournier, CEO and founder of BIOARRAY, said. “We have a highly skilled, growing team working to accelerate oncology drug discovery and development through industry and clinical partnerships.”

The new studies come shortly after funding from private investors in conjunction with Connecticut Innovations, the leading source of financing and ongoing support for Connecticut, and the 2016 election of seasoned executives Pamela Layton as president and executive chairman; and Jim LaFrance as director of the Board of Directors. Most recently, BIOARRAY signed a sponsored research agreement with UCONN Health to perform a final pre-market clinical study on the company's first clinical diagnostic for breast cancer. The company has a growing pipeline with five tests for common chemotherapies a well as immuno-oncology drugs for breast, lung and colon cancers.

More information about BIOARRAY:
http://bioarray.us/

Read the full story at http://www.prweb.com/releases/2017/04/prweb14222577.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. PreventionGenetics Receives New York License for Genetic Tests
2. Leading Family Genomics Company Good Start Genetics Expands Payor Relationships to More than 130 Million Covered Lives
3. New CAST Issue Paper: "Plant Breeding and Genetics"
4. Invitae announces expansion of its genetic testing offering to include unique test for Spinal Muscular Atrophy (SMA) during the 2017 ACMG Annual Clinical Genetics Meeting
5. Phase Genomics Proximo Hi-C Technology Featured in Nature Genetics
6. Immunomedics Enters into Exclusive Global Licensing Agreement with Seattle Genetics for Sacituzumab Govitecan (IMMU-132) with Potential Payments of up to Approximately $2 Billion, Plus Royalties
7. Preimplantation Genetics Diagnosis Market to Reach $121.50 Million, by 2022, Globally - Allied Market Research
8. Important Information Regarding the Genetics of Alzheimer’s Disease and Dementia Announced by One Million Solutions in Health™
9. Atlas Genetics Raises $35m in Series D Fundraising
10. Ovation Fertility™ Genetics Formed to Provide Accurate and Reliable PGS for IVF Clinics
11. Regeneron Genetics Center and Geisinger Study Finds Life-Threatening Genetic Disorder is Substantially Underdiagnosed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... The Blavatnik Family ... and six Finalists of the 2017 Blavatnik Regional Awards for Young Scientists. ... and administered by the New York Academy of Sciences to honor the excellence ...
(Date:10/12/2017)... ... , ... AMRI, a global contract research, development and manufacturing ... and quality of life, will now be offering its impurity solutions as a ... requirements for all new drug products, including the finalization of ICH M7 earlier ...
(Date:10/11/2017)... ... October 11, 2017 , ... Personal eye wash is a basic first aid supply ... a time. So which eye do you rinse first if a dangerous substance enters both ... Duo Eye Wash with its unique dual eye piece. , “Whether its dirt and ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
Breaking Biology Technology:
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
(Date:4/19/2017)... , April 19, 2017 The ... vendor landscape is marked by the presence of several ... however held by five major players - 3M Cogent, ... companies accounted for nearly 61% of the global military ... companies in the global military biometrics market boast global ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):